This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Early Registration Savings Deadline Expires In

  • 00
    DAYS
  • 00
    HRS
  • 00
    MINS
  • 00
    SECS
Delivered as a Hybrid Event from September 20-30, 2021
Live In-Person Experience Delivered September 20-23Boston Convention and Exhibition Center
Menu
Book
keyboard_arrow_right

CONFERENCE DAY ONE - EST/EDT (Eastern Daylight, GMT-4)

search

CONFERENCE DAY ONE - EST/EDT (Eastern Daylight, GMT-4)

search
7:00am - 8:00am60 mins
Coffee & Registration
    8:00am - 8:15am15 mins
    Chairperson’s Opening remarks
    • Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
    Plenary Session
    8:15am - 9:00am45 mins
    Joint Plenary Session
    RNAi Therapeutics: Past, Present, and (Mostly) Future
    • John Maraganore, PhD - Chief Executive Officer, Alnylam Pharmaceuticals, Inc
    9:00am - 9:45am45 mins
    Joint Plenary Session
    My Long Road from the 2’-5’ Oligos to the mRNA Vaccine
    • Katalin Karikó, PhD - Senior Vice President RNA Protein Replacement Therapy, BioNTech
    9:45am - 10:30am45 mins
    Morning Coffee and Networking
      10:30am - 11:00am30 mins
      Cell Therapy
      Adherent Cell Manufacturing & Process Development
      • Lior Raviv - Vice President Development & Operations, Pluristem Therapeutics
      10:30am - 11:00am30 mins
      Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
      Scale Up & Manufacture of CRISPR Gene Edited Hematopoietic Stem Cell (eHSC) Therapies for AML
      • Sadik H. Kassim - Chief Technology Officer, Vor Biopharma
      10:30am - 11:00am30 mins
      In Vivo Gene Therapy
      A Simple and Robust AAV Manufacturing System to Achieve High Titer And Quality Gene Therapy Vector
      • Shenjiang (Shawn) Liu - President & CEO, Avirmax Inc.
      11:00am - 11:30am30 mins
      Cell Therapy
      Risk Based Approaches to Comparability
      • Silky Kamdar - Manager, BMS
      11:00am - 11:30am30 mins
      Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
      Manufacturing Concepts for Gene-Edited Allogeneic CAR-T Cell Products
      • Chris Gemmiti, Ph.D. - Executive Director of Technical Operations; Head of Early Stage CMC and Product Launch Programs, CRISPR Therapeutics
      11:00am - 11:30am30 mins
      In Vivo Gene Therapy
      AAV Production Optimisation
      • Hélène Trottin - Senior Technical Specialist, Process Sciences, Allergan Biologics (an Abbvie company)
      11:30am - 12:00pm30 mins
      Cell Therapy
      Spotlight Presentation
        11:30am - 12:00pm30 mins
        Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
        Spotlight Presentation - CEVEC Pharmaceuticals GmbH
          11:30am - 11:50am20 mins
          In Vivo Gene Therapy
          Design, Manufacturing and Analytics of New AAV Reference Materials – A Case Study
          • Jeffrey Hung - Chief Commercial Officer, Vigene Biosciences, Inc., USA
          11:50am - 12:05pm15 mins
          In Vivo Gene Therapy
          Spotlight Presentation
            12:05pm - 1:30pm85 mins
            Lunch & Networking
              1:30pm - 2:00pm30 mins
              Cell Therapy
              Strategies for Maximizing MSC-EV Productivity and Lot Size
              • Jon A. Rowley, Ph.D. - Founder & Chief Product Officer, RoosterBio Inc.
              1:30pm - 2:00pm30 mins
              Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
              Raw Materials: BOMs, Risks & Securing Supply
              • Tom Walls - Global Planning and Logistics Lead, Spark Therapeutics, USA
              2:00pm - 2:30pm30 mins
              Cell Therapy
              iPSC Processes: Road to Automation and Closed Systems
              • Cenk Sumen - Chief Technology Officer, Stemson Therapeutics
              2:00pm - 2:30pm30 mins
              Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
              bluebird bio Supply Chain Strategy Case Study
              • Roy Sorek - Director, Quality Assurance, bluebird bio
              2:30pm - 3:00pm30 mins
              Cell Therapy
              Spotlight Presentation
                2:30pm - 3:00pm30 mins
                Gene Edited Ex Vivo Cell Therapy / In Vivo Gene Therapy
                Spotlight Presentation - CPC
                  3:00pm - 4:00pm60 mins
                  Refreshment Break in the Poster & Exhibit Hall
                    4:00pm - 4:20pm20 mins
                    Cell Therapy
                    Selection & Management of Suppliers and Contract Service Providers
                    • Ruti Goldberg - Compliance and Methods Validations Manager, Pluristem Therapeutics
                    4:00pm - 4:30pm30 mins
                    Gene Edited Ex Vivo Cell Therapy
                    Automation, Modules and Innovative Tech for End to End Processing
                    • Ali Mohamed - VP, CMC, Immatics
                    4:00pm - 4:30pm30 mins
                    In Vivo Gene Therapy
                    Developing an Integrated Manufacturing Process and Platform to Increase Speed to Clinic
                    • Alex Meola - Scientist II, Downstream Process Development, Homology Medicines
                    4:20pm - 4:40pm20 mins
                    Cell Therapy
                    Fitting Product to Process: Raw Materials Customization for Cell Therapy Manufacturing Success
                    • Lili Belcastro - Senior Scientist, Cell Therapy Dev and Ops (CTDO), Technical Center of Excellence (TCoE) for Early Development Raw Materials, BMS
                    4:30pm - 5:00pm30 mins
                    Gene Edited Ex Vivo Cell Therapy
                    PANEL: Let’s Settle the Debate – Can Auto and Allo Therapies Co-Exist
                    • Jon A. Rowley, Ph.D. - Founder & Chief Product Officer, RoosterBio Inc.
                    • Ali Mohamed - VP, CMC, Immatics
                    4:30pm - 5:00pm30 mins
                    In Vivo Gene Therapy
                    Mechanistic Modelling for the Production of Recombinant Adeno-Associated Virus via Triple Transfection of HEK293 Cells
                    • Tam Nguyen - PhD Candidate, Massachusetts Institute of Technology, USA
                    4:40pm - 5:00pm20 mins
                    Cell Therapy
                    Fitting Product to Process: Raw Materials Customization for Cell Therapy Manufacturing Success
                    • Raymond Luke - Associate Director, MS&T, Adaptimmune (pending final confirmation)
                    5:00pm - 5:30pm30 mins
                    Cell Therapy
                    Spotlight Presentation
                      5:00pm - 5:30pm30 mins
                      Gene Edited Ex Vivo Cell Therapy
                      Spotlight Presentation
                        5:00pm - 5:30pm30 mins
                        In Vivo Gene Therapy
                        Spotlight Presentation
                          5:30pm - 6:30pm60 mins
                          Grand Opening of the Poster & Exhibit Hall and Cocktail Reception
                            6:30pm - 7:00pm30 mins
                            End of Day One
                              PRE-CONFERENCE DAY
                              NextCONFERENCE DAY TWO
                              Choose Day